The possibility of Gd deposition in the pediatric brain following exposure to GBCAs is a potentially serious issue. Our study of 34 pediatric patients that received between 5 and 15 administrations of low dose (0.05 mmol/kg bodyweight) gadobenate dimeglumine (MultiHance; Bracco) revealed no differences in T1-signal in the DN, GP, pons and thalamus relative to measurements made in 24 age- and weight-matched control subjects that had never been exposed to any GBCA. Likewise no meaningful differences were seen in DN–pons and GP–thalamus SI ratios. We consider low dose gadobenate to be safe and effective for diagnosis and routine follow-up of pediatric oncologic patients.
This abstract and the presentation materials are available to members only; a login is required.